Price T Rowe Associates Inc Capricor Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
A detailed history of Price T Rowe Associates Inc transactions in Capricor Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 15,528 shares of CAPR stock, worth $170,031. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,528
Previous 14,242
9.03%
Holding current value
$170,031
Previous $197,000
24.87%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CAPR
# of Institutions
141Shares Held
17.2MCall Options Held
1.51MPut Options Held
1.02M-
Vanguard Group Inc Valley Forge, PA2.26MShares$24.8 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA2.25MShares$24.6 Million0.12% of portfolio
-
State Street Corp Boston, MA1.84MShares$20.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.63MShares$17.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA901KShares$9.87 Million0.0% of portfolio
About CAPRICOR THERAPEUTICS, INC.
- Ticker CAPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,346,200
- Market Cap $267M
- Description
- Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...